GLP1R and diabetes mellitus: In 2021, approximately 529 million people had diabetes, and this number is projected to reach 1.31 billion by 2050.5 Increasing rates of diabetes may consequently promote a rapid increase in the number of prescriptions for GLP-1 RAs in the coming years.